Literature DB >> 2578050

Normal function of CR1 on affected erythrocytes of patients with paroxysmal nocturnal hemoglobinuria.

W N Roberts, J G Wilson, W Wong, D E Jenkins, D T Fearon, K F Austen, A Nicholson-Weller.   

Abstract

Paroxysmal nocturnal hemoglobinuria (PNH) is an acquired hemolytic anemia in which affected erythrocytes (E) are abnormally sensitive to lysis by autologous complement. Affected E from patients with PNH (PNH-E) are deficient in an E membrane regulatory protein of complement, decay-accelerating factor (DAF). Because a functional defect in a second membrane regulatory protein of complement, CR1 (C3b receptor), has also been hypothesized, severely affected PNH-E (type III PNH-E) were tested for abnormalities in CR1 by four methods. E from two patients with 100% type III PNH-E had 3201 and 6783 sites per cell for binding of 125I-labeled rabbit polyclonal F(ab')2 anti-CR1. These values fall within the normal range of CR1 antigenic sites per cell (1267 to 7915, mean = 5,014 +/- 155 SEM) established by assaying the E from 113 healthy donors. The Ka of CR1 on type III PNH-E for 125I-labeled C3b dimer was 2.06 X 10(7) M-1, and the Ka values for the binding of the same ligand to the E from two healthy individuals were 2.45 X 10(7) M-1 and 1.58 X 10(7) M-1. In an assay designed to measure the capacity of human E (Eh) to accelerate the decay of the classical C3 convertase deposited on 1 X 10(7) bystander sheep E (EAC1gp,4bh,2agp), the half-life (t 1/2) of this convertase was diminished from 18.1 min (range 15.2 to 22.9) to 8.1 min (range 7.4 to 8.5) by the addition of 1 X 10(7) normal Eh, to 6.2 min by 100% type III PNH-E, and to 7.5 min by Eh pretreated with an IgG fraction of human antiserum directed against the D antigen of the Rh system. In contrast, Eh (t 1/2 = 7.4) pretreated with a saturating dose of F(ab')2 anti-CR1, and CR1-deficient Eh (less than 10 CR1 molecules/E) from a patient with systemic lupus erythematosus, showed a loss of convertase decay-accelerating capacity to t 1/2 = 11.6 and t 1/2 = 12.4, respectively. Type III PNH-E pretreated with anti-CR1 demonstrated a total loss of their decay-accelerating capacity (t 1/2 = 19.9). In an assay of I cofactor activity, soluble C3b was rapidly converted to iC3b by purified I plus Eh or type III PNH-E, whereas CR1-deficient Eh exhibited less than 5% the I cofactor activity of normal Eh.(ABSTRACT TRUNCATED AT 400 WORDS)

Entities:  

Mesh:

Substances:

Year:  1985        PMID: 2578050

Source DB:  PubMed          Journal:  J Immunol        ISSN: 0022-1767            Impact factor:   5.422


  5 in total

Review 1.  The properdin pathway: an "alternative activation pathway" or a "critical amplification loop" for C3 and C5 activation?

Authors:  Richard A Harrison
Journal:  Semin Immunopathol       Date:  2017-11-22       Impact factor: 9.623

2.  Polymorphism of the complement receptor 1 gene correlates with the hematologic response to eculizumab in patients with paroxysmal nocturnal hemoglobinuria.

Authors:  Tommaso Rondelli; Antonio M Risitano; Régis Peffault de Latour; Michela Sica; Benedetta Peruzzi; Patrizia Ricci; Wilma Barcellini; Anna Paola Iori; Carla Boschetti; Veronica Valle; Veronique Frémeaux-Bacchi; Maria De Angioletti; Gerard Socie; Lucio Luzzatto; Rosario Notaro
Journal:  Haematologica       Date:  2013-09-13       Impact factor: 9.941

3.  C3b deposition on human erythrocytes induces the formation of a membrane skeleton-linked protein complex.

Authors:  Pallop Karnchanaphanurach; Rossen Mirchev; Ionita Ghiran; John M Asara; Brigitte Papahadjopoulos-Sternberg; Anne Nicholson-Weller; David E Golan
Journal:  J Clin Invest       Date:  2009-03-02       Impact factor: 14.808

4.  Relationship between decay accelerating factor deficiency, diminished acetylcholinesterase activity, and defective terminal complement pathway restriction in paroxysmal nocturnal hemoglobinuria erythrocytes.

Authors:  M E Medof; A Gottlieb; T Kinoshita; S Hall; R Silber; V Nussenzweig; W F Rosse
Journal:  J Clin Invest       Date:  1987-07       Impact factor: 14.808

5.  Rational engineering of a minimized immune inhibitor with unique triple-targeting properties.

Authors:  Christoph Q Schmidt; Hongjun Bai; Zhuoer Lin; Antonio M Risitano; Paul N Barlow; Daniel Ricklin; John D Lambris
Journal:  J Immunol       Date:  2013-04-24       Impact factor: 5.426

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.